This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia Open Access 28 April 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kerkelä, R et al. Nat. Med. 12, 908–916 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gambacorti, C., Tornaghi, L., Franceschino, A. et al. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13, 13–14 (2007). https://doi.org/10.1038/nm0107-13b
Issue Date:
DOI: https://doi.org/10.1038/nm0107-13b
This article is cited by
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia (2016)
-
Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia
International Journal of Hematology (2013)
-
Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review
Cardiovascular Toxicology (2012)
-
Role of allo-SCT for CML in 2010
Bone Marrow Transplantation (2010)
-
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients
Bone Marrow Transplantation (2009)